17.30
0.22 (1.29%)
| Previous Close | 17.08 |
| Open | 17.24 |
| Volume | 15,478,000 |
| Avg. Volume (3M) | 9,164,016 |
| Market Cap | 46,780,059,648 |
| Price / Earnings (TTM) | 15.04 |
| Price / Sales | 2.07 |
| Price / Book | 1.88 |
| 52 Weeks Range | |
| Earnings Date | 27 Aug 2025 - 3 Sep 2025 |
| TTM Dividend Yield | 1.23% |
| Profit Margin | 14.71% |
| Operating Margin (TTM) | 13.91% |
| Diluted EPS (TTM) | 1.15 |
| Quarterly Revenue Growth (YOY) | 16.00% |
| Quarterly Earnings Growth (YOY) | 32.50% |
| Total Debt/Equity (MRQ) | 40.69% |
| Current Ratio (MRQ) | 1.75 |
| Operating Cash Flow (TTM) | 2.68 B |
| Levered Free Cash Flow (TTM) | -339.13 M |
| Return on Assets (TTM) | 4.65% |
| Return on Equity (TTM) | 12.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | PHARMARON | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.5 |
| Average | -0.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| PHARMARON | 47 B | 1.23% | 15.04 | 1.88 |
| WUXI BIO | 104 B | - | 30.18 | 2.24 |
| SINO BIOPHARM | 102 B | 1.26% | 51.73 | 2.65 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
| AKESO | 88 B | - | - | 11.02 |
| BEIGENE | 221 B | - | - | 8.31 |
|
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Institutions | 30.70% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |